PureTech Health plc

OTCPK:PRTC.Y Stock Report

Market Cap: US$450.2m

PureTech Health Future Growth

Future criteria checks 2/6

PureTech Health is forecast to grow earnings and revenue by 7.4% and 58.8% per annum respectively. EPS is expected to grow by 3.9% per annum. Return on equity is forecast to be -32.2% in 3 years.

Key information

7.4%

Earnings growth rate

3.94%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate58.8%
Future return on equity-32.20%
Analyst coverage

Low

Last updated22 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Mar 23

PureTech Health: Repeat What Works

Summary PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis (IPF) with a better tolerability profile compared to standard of care drugs. Read the full article on Seeking Alpha
Seeking Alpha • Oct 06

PureTech Health jumps 9.3% on takeover speculation

PureTech Health (NASDAQ:PRTC) soared 9.3% on some speculation that the company may be a takeover target. People following the matter have heard some speculation that PureTech (PRTC) received some takeover interest, according to a Betaville item. Developing story ...
Seeking Alpha • Aug 25

PureTech GAAP EPS of -$0.10, revenue of $7.03M

PureTech press release (NASDAQ:PRTC): 1H GAAP EPS of -$0.10. Revenue of $7.03M (+20.4% Y/Y). Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4M and Consolidated Cash and Cash Equivalents of $365.9M as of June 30, 2022, excluding up to $115.4 million added post-period ; Operational runway extended into Q1 2026.

Earnings and Revenue Growth Forecasts

OTCPK:PRTC.Y - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202836-75N/A-741
12/31/202710-119-150-1112
12/31/20265-135-140-1052
12/31/20255-110-85-85N/A
9/30/20256-30-93-93N/A
6/30/2025651-100-100N/A
3/31/2025652-117-117N/A
12/31/2024554-134-134N/A
9/30/20243-14-128-128N/A
6/30/20240-82-121-121N/A
3/31/20242-74-114-113N/A
12/31/20233-66-106-106N/A
9/30/20238-56-132-131N/A
6/30/202312-47-157-157N/A
3/31/202314-49-169-168N/A
12/31/202216-50-181-179N/A
9/30/202217-32-183-179N/A
6/30/202219-14-185-180N/A
3/31/202218-37-174-169N/A
12/31/202117-61-164-158N/A
9/30/202114-127-156-150N/A
6/30/202111-193-147-141N/A
3/31/202111-94-142-136N/A
12/31/2020126-137-132N/A
9/30/202012239-121-115N/A
6/30/202012472-104-99N/A
3/31/202011446-107-99N/A
12/31/201910421-111-98N/A
9/30/201915229N/A-91N/A
6/30/20192037N/A-84N/A
3/31/201920-3N/A-78N/A
12/31/201821-44N/A-73N/A
9/30/2018149N/A-81N/A
6/30/2018761N/A-88N/A
3/31/2018544N/A-88N/A
12/31/2017326N/A-89N/A
9/30/20174-17N/A-81N/A
6/30/20175-61N/A-74N/A
3/31/20175-55N/A-66N/A
12/31/20164-49N/A-58N/A
9/30/20163-54N/A-57N/A
6/30/20161-59N/A-55N/A
3/31/20166-49N/A-42N/A
12/31/201512-39N/A-29N/A
9/30/201512-37N/A-19N/A
6/30/201512-35N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTC.Y is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRTC.Y is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRTC.Y is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRTC.Y's revenue (58.8% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: PRTC.Y's revenue (58.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PRTC.Y is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 08:52
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PureTech Health plc is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter WelfordJefferies LLC
Miles DixonPeel Hunt LLP
Edward TenthoffPiper Sandler Companies